As of Friday close, Apellis Pharmaceuticals Inc.’s (NASDAQ:APLS) stock was down -$3.23, moving down -6.87 percent to $43.77. The average number of shares traded per day over the past five days has been 3,767,460 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.67 fall in that time frame. In the last twenty days, the average volume was 2,545,625, while in the previous 50 days, it was 5,811,996.
Since last month, APLS stock rose 9.32%. Shares of the company fell to $38.72 on 08/24/23, the lowest level in the past month. A 52-week high of $94.75 was reached on 06/14/23 after having rallying from a 52-week low of $19.83. Since the beginning of this year, APLS’s stock price has dropped by -15.35% or -$7.94, and marked a new high 22 times. However, the stock has declined by -53.80% since its 52-week high.
APLS stock investors should be aware that Apellis Pharmaceuticals Inc. (APLS) stock had its last reported insider trading activity 5 days ago on Sep 18. Nicholson Nur, the Chief Technical Officer of the company, disposed of 20,350 shares for $44.27 on Sep 18. It resulted in a $900,813 divestment by the insider. Machiels Alec sold 1,250 shares at an average price of $45.00 on Sep 18. The insider now owns 367,420 shares following the transaction. On Sep 15, Director Machiels Alec sold 1,250 shares at $45.34 apiece. The transaction was valued at $56,675.
Valuation Metrics
The stock’s beta is 1.04. Besides these, the trailing price-to-sales (P/S) ratio of 27.22, the price-to-book (PB) ratio of 15.15.
Financial Health
In the three months ended June 29, Apellis Pharmaceuticals Inc.’s quick ratio stood at 4.50, while its current ratio was 5.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 1.11, and the total debt-to-equity ratio was 1.24. On the profitability front, the trailing twelve-month gross margin is 88.90% percent. Based on annual data, APLS earned $69.79 million in gross profit and brought in $75.42 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -103.40%. Return on equity (ROE) for the past 12 months was -212.80%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. APLS’s revenue rose 82.82% to $44.85 million during the quarter, while net income inched up to $94.97 million. While analysts expected Apellis Pharmaceuticals Inc. to report -$1.32 quarterly earnings, the actual figure was -$1.02 per share, beating the consensus estimate by 22.70%. During the quarter, the company generated -$106.88 million in EBITDA. The liabilities of Apellis Pharmaceuticals Inc. were 570.17 million at the end of its most recent quarter ended June 29, and its total debt was $110.8 million. The value of shareholders’ equity is $117.74 million.
Technical Picture
This quick technical analysis looks at Apellis Pharmaceuticals Inc.’s (APLS) price momentum. With a historical volatility rate of 55.40%, the RSI 9-day stood at 50.62% on 22 September.
With respect to its five-day moving average, the current Apellis Pharmaceuticals Inc. price is down by -1.51% percent or -$0.67. At present, APLS shares trade +9.21% above its 20-day simple moving average and -47.21% percent below its 100-day simple moving average. However, the stock is currently trading approximately -49.09% below its SMA50 and -11.36% below its SMA200.
Stochastic coefficient K was 52.45% and Stochastic coefficient D was 66.68%, while ATR was 3.00. Given the Stochastic reading of 27.65% for the 14-day period, the RSI (14) reading has been calculated as 52.50%. As of today, the MACD Oscillator reading stands at 1.20, while the 14-day reading stands at 2.22.
Analyst Ratings
Wells Fargo upgraded its rating on Apellis Pharmaceuticals Inc. (NASDAQ: APLS) to an Overweight in a note to investors on September 15, 2023. The analysts firm previously had an Equal weight rating on the stock.Apellis Pharmaceuticals Inc. (APLS) has been rated Overweight by analysts. According to 0 brokerage firms, APLS is a sell, and 4 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Apellis Pharmaceuticals Inc. stock as buy, with 10 recommending it as overweight.
With a median target price of $64.50, the current consensus forecast for the stock is $29.00 – $95.00. Based on these forecasts, analysts predict Apellis Pharmaceuticals Inc. (APLS) will achieve an average price target of $67.64.
